Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vivotif + dukoral
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Vivotif + Dukoral is a combination of two oral vaccines. Vivotif is a live typhoid vaccine administered orally in capsule form to help prevent typhoid fever caused by Salmonella typhi. Dukoral is an oral cholera vaccine. The combination is being studied for coadministration to determine if there are any impacts on the immune responses to either vaccine when given simultaneously.
- Brand names
- Vivotif + Dukoral
- Other names
- cholera vaccine + typhoid vaccine live oral
02
Targets
GM1 (GM1 ganglioside)
Beyond the preview
Go deeper on vivotif + dukoral.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vivotif + dukoral.